Sugi Predict

Sugi Predict / Compounds / SCHEMBL799651

SCHEMBL799651

SCHEMBL799651

N=C(N)Cc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR3E A5X5Y0 2/20 0.59
▸ HTR3B O95264 2/20 0.59
▸ HTR3A P46098 2/20 0.59
▸ HTR3D Q70Z44 2/20 0.59
▸ HTR3C Q8WXA8 2/20 0.59
▸ IDO1 P14902 6/20 0.57
▸ LMNA P02545 1/20 0.48
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ TAAR1 Q96RJ0 1/20 0.44
▸ SLC6A4 P31645 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ AGXT P21549 1/20 0.43
▸ CTBP2 P56545 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL216057 0.98 IDO1 (0.59) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL16275249 0.80 NOS1 (0.48) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL4636749 0.78 MASP2 (0.48) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2700841 0.78 LOXL2 (0.60) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1520205 0.78 CA2 (0.60) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL4847288 0.77 IDO1 (0.58) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1999167 0.76 IDO1 (0.52) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL799654 0.76 CA2 (0.64) LMNACYP2C9CYP2C19L3MBTL1CTBP2
SCHEMBL20008634 0.76 IDO1 (0.57) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL10558734 0.76 IDO1 (0.47) IDO1LMNATAAR1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115957616-A Desulfurization filler and preparation and application thereof 中国石油化工股份有限公司 2023-04-14 — — CN claimed
CN-115957725-A Modified hollow ceramic fiber and preparation method and application thereof 中国石油化工股份有限公司 2023-04-14 — — CN claimed
US-4522763-A STARTING MATERIALS FOR CROP PROTECTION AGENTS AND SELECTIVE HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1985-06-11 — — US claimed
WO-2025011546-A1 HUMAN CASEINOLYTIC PROTEASE P AGONISTS AND USES THEREOF ACELON THERAPEUTICS (CN) 2025-01-16 — — WO disclosed
US-20240390301-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS GILGAMESH PHARMACEUTICALS, INC. (US) 2024-11-28 — — US disclosed
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-11-07 — — US disclosed
CN-115957725-A Modified hollow ceramic fiber and preparation method and application thereof 中国石油化工股份有限公司 2023-04-14 — — CN disclosed
CN-115957616-A Desulfurization filler and preparation and application thereof 中国石油化工股份有限公司 2023-04-14 — — CN disclosed
WO-2023028086-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-03-02 — — WO disclosed
US-9539256-B2 Modulators of exchange proteins directly activated by cAMP (EPACS) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-01-10 — — US disclosed
US-20120071663-A1 Preparation of N'-(4--2,5-dimethylphenyl)-N- ethyl-N-methylimidoformamide BAYER CROPSCIENCE AG (DE) 2012-03-22 — — US disclosed
US-20100113422-A1 Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists ANDREWS MARK 2010-05-06 — — US disclosed
EP-2139896-A1 PYRIMIDO [4, 5-D]AZEPINE DERIVATIVES AS 5-HT2C AGONISTS Pfizer Limited (GB) 2010-01-06 — — EP disclosed
WO-2008117169-A1 PYRIMIDO [4, 5-D] AZEPINE DERIVATIVES AS 5-HT2C AGONISTS PFIZER LIMITED (GB) 2008-10-02 — — WO disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 — — WO disclosed
EP-1890702-A1 USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Bayer HealthCare AG (DE) 2008-02-27 — — EP disclosed
WO-2006125554-A1 USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2006-11-30 — — WO disclosed
US-4522763-A STARTING MATERIALS FOR CROP PROTECTION AGENTS AND SELECTIVE HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1985-06-11 — — US disclosed
EP-0073442-B1 N-ALKOXYCARBONYL AND N-ALKOXYTHIOCARBONYL AMIDINES AND PREPARATION THEREOF BASF Aktiengesellschaft (DE) 1985-03-13 — — EP disclosed
EP-0073442-A2 N-alkoxycarbonyl and N-alkoxythiocarbonyl amidines and preparation thereof BASF Aktiengesellschaft (DE) 1983-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240390301-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS HTR2A, HTR2C, HTR5A HTR3E 15/4885HTR3B 7/4885HTR3A 6/4885
US-20120071663-A1 Preparation of N'-(4--2,5-dimethylphenyl)-N- ethyl-N-methylimidoformamide NT5C, NT5E, NT5C3B HTR3E 503/4885HTR3B 498/4885HTR3A 403/4885
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER BICRA, BRD4, CNR1 HTR3E 157/4885HTR3B 61/4885HTR3A 24/4885
US-20100113422-A1 Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists HTR2C, HTR2A, HTR5A HTR3E 13/4885HTR3B 7/4885HTR3A 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.